. 2022 Jun;14(6):1772–1783. doi: 10.21037/jtd-21-1377
2022 Journal of Thoracic Disease. All rights reserved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.
Figure 3.
Median PFS with immunotherapy stratified by tumor mutational burden. PFS, progression-free survival.